The purpose of the GENETIC-AF study was to determine if pharmacogenetically targeted bucindolol is superior to Toprol-XL for reducing the recurrence of symptomatic atrial fibrillation/atrial flutter (AF/AFL) in a genotype-defined population with heart failure and/or reduced left ventricular ejection fraction (LVEF) and persistent symptomatic AF requiring electrical cardioversion to sinus rhythm.

Primary endpoint:

Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all-cause mortality (ACM) during the 24-week follow-up period after conversion to stable sinus rhythm.

Study Type

Interventional - Drug

Study Design

Double blind 2 arm active controlled adaptive design superiority

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2014 - 2017


ARCA Biopharma

Back To Top